Torabi Sarah, Ahmadzade Mohadese, Ghorani Hamed, Sarvari Masoumeh, Rouientan Hamidreza, Trinh Kelly, Manzari Tavakoli Gita, Afsharzadeh Mahshad, Uppot Raul Nirmal, Ghasemi-Rad Mohammad
Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Medical Imaging Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Skeletal Radiol. 2025 Jan 31. doi: 10.1007/s00256-025-04877-7.
To assess the efficacy of cryoablation in controlling pain from metastatic bone lesions.
A systematic search of PubMed, Embase, Scopus, Cochrane library, and Web of Science was conducted from inception to April 2024, focusing on cryoablation for palliation of painful bone metastases. The inclusion criteria were as follows: studies involving patients over 18 years of age who were affected by bone metastases; bone metastases treated with stand-alone cryoablation; studies reporting patients' pain levels before and at least at one time point after cryoablation; and studies published in English.
A total of 844 articles were initially screened, resulting in 12 articles involving 309 patients included. Pain assessments were conducted at various time points ranging from 1 day to 6 months after the cryoablation procedure. Included studies reported significant improvements in pain scores based on the visual analog scale (VAS), the numeric rating scale (NRS) and brief pain inventory-short form (BPI-SF) following treatment at 1, 4, 8 and 12 weeks. The most notable mean difference between pre- and post-procedure pain scores was observed at 12 weeks, with a standardized mean difference of -3.71 (95% confidence interval [CI]: -5.29 to -2.00; p < 0.001). Regarding pain relief outcomes, by the fourth week, the proportion of patients experiencing pain relief was 0.69 (95% CI: 0.62 to 0.75; p < 0.001).
Cryoablation could be an effective method for palliation of painful bone metastases. Further studies are needed to compare its efficacy with other palliative methods and to define its role in cancer management.
评估冷冻消融术控制转移性骨肿瘤疼痛的疗效。
从数据库建库至2024年4月,对PubMed、Embase、Scopus、Cochrane图书馆及Web of Science进行系统检索,重点关注冷冻消融术缓解骨转移瘤疼痛的研究。纳入标准如下:研究对象为年龄超过18岁的骨转移患者;单独采用冷冻消融术治疗骨转移;研究报告患者冷冻消融术前及术后至少一个时间点的疼痛水平;研究以英文发表。
初步筛选出844篇文章,最终纳入12篇文章,涉及309例患者。在冷冻消融术后1天至6个月的不同时间点进行疼痛评估。纳入研究报告称,在术后1、4、8和12周,基于视觉模拟量表(VAS)、数字评分量表(NRS)和简明疼痛问卷简表(BPI-SF)的疼痛评分有显著改善。术前和术后疼痛评分的最显著平均差异出现在12周,标准化平均差异为-3.71(95%置信区间[CI]:-5.29至-2.00;p<0.001)。关于疼痛缓解结果,到第四周,经历疼痛缓解的患者比例为0.69(95%CI:0.62至0.75;p<0.001)。
冷冻消融术可能是缓解骨转移瘤疼痛的有效方法。需要进一步研究将其疗效与其他姑息治疗方法进行比较,并确定其在癌症治疗中的作用。